The medical devices industry continues to be a hotbed of patent innovation. Activity is driven by increased need for homecare, preventative treatments, early diagnosis, reducing patient recovery times and improving outcomes, as well as a growing importance in technologies, such as machine learning, augmented reality, 5G, and digitalization. In the last three years alone, there have been over 710,000 patents filed and granted in the medical devices industry, according to GlobalData’s report on Internet of Things in medical: dosage monitoring inhalators. Buy the report here.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
30+ innovations will shape the medical devices industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the medical devices industry using innovation intensity models built on over 155,000 patents, there are 30+ innovation areas that will shape the future of the industry.
Within the emerging innovation stage, programmable infusion devices, wearable sleep assistance devices, and context-aware patient monitoring are disruptive technologies that are in the early stages of application and should be tracked closely. Remote dialysis monitoring, NFC implants, and medical ERS are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas is body area network (BAN), which is now well established in the industry.
Innovation S-curve for Internet of Things in the medical devices industry
Dosage monitoring inhalators is a key innovation area in Internet of Things.
Dosage monitoring inhalators are a device that diffuses drugs into a patient's lungs. they contains sensors to monitor and track the dosage to ensure the patient is receiving what has been recommended by the physician. Metered dose inhalers (MDIs) are available as nasal or oral inhalers, which are valued by patients on therapy related to respiratory illnesses, such as asthma or chronic obstructive pulmonary disease.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 90+ companies, spanning technology vendors, established medical devices companies, and up-and-coming start-ups engaged in the development and application of dosage monitoring inhalators.
Key players in dosage monitoring inhalators– a disruptive innovation in the medical devices industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to dosage monitoring inhalators
Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
C. H. Boehringer Sohn AG & Co KG | 464 | Unlock Company Profile |
Teva Pharmaceutical Industries Ltd | 296 | Unlock Company Profile |
AptarGroup Inc | 273 | Unlock Company Profile |
GSK plc | 100 | Unlock Company Profile |
Pneuma Respiratory Inc | 77 | Unlock Company Profile |
Recipharm AB | 68 | Unlock Company Profile |
Koninklijke Philips NV | 55 | Unlock Company Profile |
MannKind Corp | 52 | Unlock Company Profile |
MicroBase Technology Corp | 52 | Unlock Company Profile |
Metall Zug AG | 48 | Unlock Company Profile |
British American Tobacco Plc | 44 | Unlock Company Profile |
Syqe Medical Ltd | 43 | Unlock Company Profile |
ResMed Inc | 41 | Unlock Company Profile |
Chiesi Farmaceutici SpA | 38 | Unlock Company Profile |
Adherium Ltd | 33 | Unlock Company Profile |
Becton Dickinson and Co | 32 | Unlock Company Profile |
Laboratoires Thea SA | 32 | Unlock Company Profile |
Charoen Pokphand Group Co Ltd | 28 | Unlock Company Profile |
Shl Medical Ag | 17 | Unlock Company Profile |
Johnson & Johnson | 15 | Unlock Company Profile |
GoFire Inc | 14 | Unlock Company Profile |
Trudell Medical International | 14 | Unlock Company Profile |
WellO2 Oy | 13 | Unlock Company Profile |
Proveris Scientific Corp | 12 | Unlock Company Profile |
Cipla Ltd | 12 | Unlock Company Profile |
Heitkamp & Thumann KG | 12 | Unlock Company Profile |
Teleflex Inc | 12 | Unlock Company Profile |
Embracer Group AB | 12 | Unlock Company Profile |
Philip Morris International Inc | 11 | Unlock Company Profile |
iDTx Systems, Inc. | 10 | Unlock Company Profile |
Qualcomm Inc | 10 | Unlock Company Profile |
Intellectual Ventures Management LLC | 10 | Unlock Company Profile |
Convexity Scientific LLC | 10 | Unlock Company Profile |
Novartis AG | 10 | Unlock Company Profile |
Mystic Pharmaceuticals Inc | 9 | Unlock Company Profile |
Sulzer Mixpac AG | 9 | Unlock Company Profile |
Nipro Corp | 8 | Unlock Company Profile |
Glatton Sp zoo | 8 | Unlock Company Profile |
MediTuner AB | 8 | Unlock Company Profile |
Pneumoflex Systems LLC | 8 | Unlock Company Profile |
Amiko Digital Health Ltd | 7 | Unlock Company Profile |
Sanofi | 7 | Unlock Company Profile |
Inhalation Sciences Sweden AB | 7 | Unlock Company Profile |
Materialise NV | 7 | Unlock Company Profile |
Sumitomo Chemical Co Ltd | 7 | Unlock Company Profile |
Daikyo Seiko Ltd | 7 | Unlock Company Profile |
Hava Health Inc | 7 | Unlock Company Profile |
SipNose | 6 | Unlock Company Profile |
Francisco Partners Management LLC | 6 | Unlock Company Profile |
Alphabet Inc | 6 | Unlock Company Profile |
Source: GlobalData Patent Analytics
C. H. Boehringer Sohn and Teva Pharmaceutical Industries are two of the leading patent filers in dosage monitoring inhalators. Some other leading patent filers include AptarGroup, GSK, Recipharm, Pneuma Respiratory, Recipharm, and Koninklijke Philips.
In terms of application diversity, Materialise leads the pack, followed by Syqe Medical and British American Tobacco. By geographic reach, Syqe Medical holds the top position, followed by Pneuma Respiratory and Teva Pharmaceutical Industries in second and third spots, respectively.
The market for dosage monitoring inhalators will be driven by increased access to medication across multiple therapeutic areas for a broader spectrum of patients and the development of combination products while ensuring affordability.
To further understand the key themes and technologies disrupting the medical devices industry, access GlobalData’s latest thematic research report on Medical Devices.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.